M&A Deal Summary

Roivant Sciences Acquires Silicon Therapeutics

On February 26, 2021, Roivant Sciences acquired life science company Silicon Therapeutics for 450M USD

Acquisition Highlights
  • This is Roivant Sciences’ 1st transaction in the Life Science sector.
  • This is Roivant Sciences’ largest (disclosed) transaction.
  • This is Roivant Sciences’ 1st transaction in the United States.
  • This is Roivant Sciences’ 1st transaction in Massachusetts.

M&A Deal Summary
Date 2021-02-26
Target Silicon Therapeutics
Sector Life Science
Buyer(s) Roivant Sciences
Deal Type Add-on Acquisition
Deal Value 450M USD

Target

Silicon Therapeutics

Boston, Massachusetts, United States
Silicon Therapeutics LLC is a fully integrated drug design and development company focused on small molecule therapeutics. The Silicon Therapeutics proprietary physics-driven drug design platform combines quantum physics, statistical thermodynamics, molecular simulations, a dedicated HPC super-computing cluster, purpose-built software, in-house laboratories and clinical development capabilities. Silicon Therapeutics is based in Boston, Massachusetts.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Roivant Sciences

London, United Kingdom
Category Company
Founded 2014
Sector Life Science
Employees908
Revenue 125M USD (2024)
DESCRIPTION

Roivant Sciences develops transformative medicines faster by building technologies and developing talent in creative ways, leveraging the Roivant platform to launch Vants – nimble and focused biopharmaceutical and health technology companies. Roivant Sciences was founded in 2014 and is based in London, United Kingdom.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (Massachusetts) 1 of 1
Country (United States) 1 of 1
Year (2021) 1 of 1
Size (of disclosed) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2023-10-23 Telavant

New York, New York, United States

Telavant is the developer of RVT-3101, a novel TL1A directed antibody. RVT-3101 is a therapy in development for people suffering from inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. Telavant is based in New York, New York.

Sell $7.1B
Mergr

Product

Company

Legal